Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franciane Paul

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Expert Review of Clinical Immunology|December 25, 2018
Infusion-related reactions to rituximab: frequency, mechanisms and predictorsFranciane Paul, Guillaume Cartron
Gene|May 19, 2015
IFNA2: The prototypic human alpha interferonFranciane Paul, Sandra Pellegrini, Gilles Uzé
La Revue Du Praticien|March 13, 2010
[Monoclonal antibody therapy for non-Hodgkin's lymphoma]Franciane Paul, Jean-François Rossi, Guillaume Cartron
Leukemia & Lymphoma|November 22, 2021
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO studyAnne Laure Gagez, Franciane Paul, Elina Alaterre, et al.
Journal of Autoimmunity|November 24, 2018
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in miceAnje Cauwels, Sandra Van Lint, Dominiek Catteeuw, et al.
Bulletin Du Cancer|January 31, 2022
[Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC]Muriel Picard, Arthur Sterin, Jacques-Olivier Bay, et al.
Bulletin Du Cancer|December 8, 2021
[Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Franciane Paul, Céline Vicente, Corinne Courbon, et al.
Nature Communications|January 9, 2014
High efficiency cell-specific targeting of cytokine activityGeneviève Garcin, Franciane Paul, Markus Staufenbiel, et al.
Bulletin Du Cancer|November 22, 2021
[Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)]Cécile Pochon, Corinne Courbon, Jacques-Olivier Bay, et al.
Bulletin Du Cancer|December 13, 2021
[Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Expert Review of Clinical Immunology|December 25, 2018
Infusion-related reactions to rituximab: frequency, mechanisms and predictorsFranciane Paul, Guillaume Cartron
Gene|May 19, 2015
IFNA2: The prototypic human alpha interferonFranciane Paul, Sandra Pellegrini, Gilles Uzé
La Revue Du Praticien|March 13, 2010
[Monoclonal antibody therapy for non-Hodgkin's lymphoma]Franciane Paul, Jean-François Rossi, Guillaume Cartron
Leukemia & Lymphoma|November 22, 2021
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO studyAnne Laure Gagez, Franciane Paul, Elina Alaterre, et al.
Journal of Autoimmunity|November 24, 2018
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in miceAnje Cauwels, Sandra Van Lint, Dominiek Catteeuw, et al.
Bulletin Du Cancer|January 31, 2022
[Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC]Muriel Picard, Arthur Sterin, Jacques-Olivier Bay, et al.
Bulletin Du Cancer|December 8, 2021
[Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Franciane Paul, Céline Vicente, Corinne Courbon, et al.
Nature Communications|January 9, 2014
High efficiency cell-specific targeting of cytokine activityGeneviève Garcin, Franciane Paul, Markus Staufenbiel, et al.
Bulletin Du Cancer|November 22, 2021
[Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)]Cécile Pochon, Corinne Courbon, Jacques-Olivier Bay, et al.
Bulletin Du Cancer|December 13, 2021
[Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, et al.
Pageof 3